PMID- 24155038
OWN - NLM
STAT- MEDLINE
DCOM- 20160602
LR  - 20150902
IS  - 1880-4233 (Electronic)
IS  - 1340-6868 (Linking)
VI  - 22
IP  - 5
DP  - 2015 Sep
TI  - The impact of Girdin expression on recurrence-free survival in patients with 
      luminal-type breast cancer.
PG  - 445-51
LID - 10.1007/s12282-013-0501-3 [doi]
AB  - BACKGROUND: In patients with luminal-type breast cancer (positive for ER and/or 
      PgR), a complete consensus on the threshold indication for a combination of 
      chemotherapy and endocrine therapy has not been achieved, especially for patients 
      with HER2-negative luminal type (HNLT). Girdin, an actin-binding Akt substrate, 
      plays a crucial role in the migration of cancer cells. This study examined the 
      expression of Girdin in relation to clinicopathological features and other 
      immunohistochemical markers (HER2, Ki-67), especially in patients with HNLT 
      breast cancer. METHODS: One hundred one breast cancer patients who underwent 
      surgery were evaluated. Immunohistochemical staining was performed for Girdin and 
      other biomarkers, such as ER, PgR, HER2, and Ki-67. RESULTS: Positive expression 
      of Girdin was observed in 26 patients. The expression of Girdin was significantly 
      associated with the incidence of lymph node metastases (p = 0.001). Among the 
      other examined biomarkers, positive expression of Ki-67 also showed a significant 
      association with the incidence of lymph node metastases (p = 0.04). In the HNLT 
      breast cancer patients (n = 73), the 5-year recurrence-free survival rate was 
      significantly lower (57 %) in patients with positive expression of both Girdin 
      and Ki-67 than the rate in other patients (92 %) (p = 0.002). CONCLUSION: This 
      study demonstrated that the expression of Girdin in invasive breast cancer is 
      strongly associated with lymph node metastasis. The expression status of Girdin 
      and Ki-67 can be a useful biomarker in stratifying patients with HNLT breast 
      cancer into those with high risk of recurrence and the need for additional 
      chemotherapy.
FAU - Nishimae, Kazumi
AU  - Nishimae K
AD  - Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate 
      School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
FAU - Tsunoda, Nobuyuki
AU  - Tsunoda N
FAU - Yokoyama, Yukihiro
AU  - Yokoyama Y
FAU - Kokuryo, Toshio
AU  - Kokuryo T
FAU - Iwakoshi, Akari
AU  - Iwakoshi A
FAU - Takahashi, Masahide
AU  - Takahashi M
FAU - Nagino, Masato
AU  - Nagino M
LA  - eng
PT  - Journal Article
DEP - 20131024
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - 0 (CCDC88A protein, human)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Microfilament Proteins)
RN  - 0 (Vesicular Transport Proteins)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*metabolism/*mortality/*pathology/therapy
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen/metabolism
MH  - Lymphatic Metastasis/pathology
MH  - Microfilament Proteins/*metabolism
MH  - Middle Aged
MH  - Receptor, ErbB-2/metabolism
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Vesicular Transport Proteins/*metabolism
EDAT- 2013/10/25 06:00
MHDA- 2016/06/03 06:00
CRDT- 2013/10/25 06:00
PHST- 2013/07/16 00:00 [received]
PHST- 2013/09/24 00:00 [accepted]
PHST- 2013/10/25 06:00 [entrez]
PHST- 2013/10/25 06:00 [pubmed]
PHST- 2016/06/03 06:00 [medline]
AID - 10.1007/s12282-013-0501-3 [doi]
PST - ppublish
SO  - Breast Cancer. 2015 Sep;22(5):445-51. doi: 10.1007/s12282-013-0501-3. Epub 2013 
      Oct 24.